Abstract:Abstract Objective: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world. T cells are very important in the body's anti-tumor process. However, in HCC, T cell exhaustion not only makes it difficult to implement CAR-T therapy, but also reduces the body's anti-tumor ability or even promotes tumor development. Therefore, it is urgent to explore the relationship between positive regulators of T cells proliferation and HCC. Methods: HCC transcriptome and clinical data were collected from TCGA and ICGC databases. Differentially expressed T-cell positive regulators in the TCGA dataset were analyzed using the R software "limma" package. Univariate COX and Least Absolute Value Convergence and Selection Operator (LASSO) regression analysis established a T cell positive regulator prognostic model, and further combined the risk score with clinicopathological features to construct a nomogram. Single-gene enrichment analysis (ssGSEA) was performed using the R software "gva" package to compare the proportion of immune cells between high and low score groups, and gene set variation (GSVA) to identify significantly enriched signaling pathways in high and low score groups. The "pRRophetic" R software package analyzes the susceptibility of patients with high and low scores to chemotherapy. Further, GO and KEGG pathway enrichment analysis was performed on the differential genes in the high and low score groups, and the "cytoHubba" software was used to find the key differential genes in the high and low score groups.Results: A total of 33 positive regulators of T cell proliferation were identified, and 617 HCC patients were included in the analysis. Among them, 23 T cell positive regulators were significantly differentially expressed in HCC (P<0.05). Patients with high scores in the TCGA dataset had poorer prognosis than those with lower scores, and the results were consistent with the validation results in the ICGC dataset (P<0.05). The levels of antigen-presenting cells, major histocompatibility complex-I, chemokine receptors and immune checkpoints in the high-scoring group were significantly increased (P<0.05). The IC50 values of 5-FU, doxorubicin and mitomycin were significantly lower in the high score group (P<0.05). The highly expressed genes in the high score group were mainly enriched in signaling pathways such as RNA degradation, cell cycle, mismatch repair, and DNA replication, and the highly expressed genes in the low score group were mainly enriched in metabolism-related pathways. The top three key differential genes in the high and low risk groups were CDK1, KIF11, and TOP2A. The prognosis of HCC patients with high expression of CDK1 and low expression was significantly worse (P<0.05), and it was related to clinical stage.Conclusion: The positive regulators of T cell proliferation are significantly differentially expressed in HCC, and the overexpression of related genes brings hope for the application of CAR-T therapy in HCC. The prognostic model of T cell positive regulators promotes the understanding of the characteristics of HCC tumor immune microenvironment infiltration and drug sensitivity, and provides a theoretical basis for the clinical treatment of HCC.

The Prognostic Significance of CTSV Expression in Patients with Hepatocellular Carcinoma

Cathepsin V is Correlated with the Prognosis and Tumor Microenvironment in Liver Cancer.

Prognostic significance and oncogene function of cathepsin A in hepatocellular carcinoma

Increased expression of cathepsin L: a novel independent prognostic marker of worse outcome in hepatocellular carcinoma patients.

Gene-based cancer-testis antigens as prognostic indicators in hepatocellular carcinoma

Integrative study reveals the prognostic and immunotherapeutic value of CTCs/CTMs -related prognostic signature in Hepatocellular carcinoma

Bioinformatics analysis and experimental validation of cystathionine-gamma-lyase as a potential prognosis biomarker in hepatocellular carcinoma

Expression and prognostic value of Cystatin B in hepatocellular carcinoma

Survivin-positive circulating tumor cells as a marker for metastasis of hepatocellular carcinoma

Identification of CERS5 as a novel biomarker for prognosis and immunity in hepatocellular carcinoma: a bioinformatics analysis and functional validation study

Characterization of positively regulate T cell proliferation-related genes in hepatocellular cancer to guide clinical therapy

Identification of Ribosomal Protein S21 As a Potential Prognostic and Immunotherapy Biomarker for Hepatocellular Carcinoma

Development of a Novel CD8+ T Cell-Associated Signature for Prognostic Assessment in Hepatocellular Carcinoma

Circulating Tumor Cells for Predicting the Prognostic of Patients with Hepatocellular Carcinoma: A Meta Analysis.

Clinical and Prognostic Value of PPIA, SQSTM1, and CCL20 in Hepatocellular Carcinoma Patients by Single-Cell Transcriptome Analysis

A Novel Gene Pair CSTF2/DPE2A Impacts Prognosis and Cell Cycle of Hepatocellular Carcinoma

Establishment and Validation of a Novel CD8+ T Cell-Associated Prognostic Signature for Predicting Clinical Outcomes and Immunotherapy Response in Hepatocellular Carcinoma Via Integrating Single-Cell RNA-seq and Bulk RNA-seq.

Prognostic significance of HS2ST1 expression in patients with hepatocellular carcinoma

LPCAT1 Acts As an Independent Prognostic Biomarker Correlated with Immune Infiltration in Hepatocellular Carcinoma

Protein Expression Profiling of Vascular Endothelial Growth Factor and Its Receptors Identifies Subclasses of Hepatocellular Carcinoma and Predicts Survival